WO1998006444A1 - Mousses destinees a la coagulation du sang, a base de collagene, procede et dispositifs permettant de les administrer - Google Patents

Mousses destinees a la coagulation du sang, a base de collagene, procede et dispositifs permettant de les administrer Download PDF

Info

Publication number
WO1998006444A1
WO1998006444A1 PCT/US1997/014263 US9714263W WO9806444A1 WO 1998006444 A1 WO1998006444 A1 WO 1998006444A1 US 9714263 W US9714263 W US 9714263W WO 9806444 A1 WO9806444 A1 WO 9806444A1
Authority
WO
WIPO (PCT)
Prior art keywords
collagen
composition
foam
container
fetal
Prior art date
Application number
PCT/US1997/014263
Other languages
English (en)
Inventor
Eugene Bell
Tracy M. Sioussat
Original Assignee
Tissue Engineering, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tissue Engineering, Inc. filed Critical Tissue Engineering, Inc.
Priority to AU40652/97A priority Critical patent/AU4065297A/en
Publication of WO1998006444A1 publication Critical patent/WO1998006444A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
    • A61L24/04—Surgical adhesives or cements; Adhesives for colostomy devices containing macromolecular materials
    • A61L24/10—Polypeptides; Proteins
    • A61L24/102—Collagen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
    • A61L26/0009—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials
    • A61L26/0028—Polypeptides; Proteins; Degradation products thereof
    • A61L26/0033—Collagen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
    • A61L26/0061—Use of materials characterised by their function or physical properties
    • A61L26/0076—Sprayable compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
    • A61L26/0061—Use of materials characterised by their function or physical properties
    • A61L26/0085—Porous materials, e.g. foams or sponges
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2400/00—Materials characterised by their function or physical properties
    • A61L2400/04—Materials for stopping bleeding

Definitions

  • hypovolemia secondary to hemorrhage
  • internal bleeding due to, for example, traumatic injuries or internal bleeding occurring postoperatively, can also lead to extensive and dangerous blood loss.
  • materials include simple cotton gauze dressings used principally for external bleeding. Such dressings have the disadvantage of being passive dressings which are unable to initiate or accelerate blood clotting.
  • fibrin glue Another material, available for use in Europe but not in the United States, is fibrin glue, which forms upon the combination of fibrinogen and thrombin solutions.
  • fibrin glue has the major drawback of carrying with its use a risk of transmitting serological disease from donated human blood, the source of the proteins.
  • the requirement that the two components, fibrinogen and thrombin, be combined at the moment of use can be time-consuming.
  • Thrombin alone, as a powder or in solution, produced by Parke-Davis under the tradename Thrombostat® is another hemostatic product.
  • the thrombin solution which includes calcium chloride, sodium chloride and glycine, must be constituted at the moment of its use.
  • Thrombostat® has not been approved by the United States Food and Drug Administration for use in humans.
  • other hemostatic agents such as collagen-based hemostatic agents have been developed.
  • Collagen is the protein to which platelets normally attach when they escape from the vascular system.
  • the vessels comprising the vascular system are surrounded by networks of collagen fibrils which are also present throughout the tissues of the body.
  • the normally disc-shaped platelets Upon contact with the collagen, the normally disc-shaped platelets become spherical, extend filopodia, and release ADP, calcium, 5-hydroxytryptamine, serotonin, prostaglandins, thromboxane A2 and initiate the blood clotting cascade of the intrinsic pathway through activation of factor XII.
  • the foregoing chemicals released by attached platelets initiate binding of other platelets to those already adhering to the collagen.
  • the result is platelet aggregation and triggering of platelet activation leading to formation of a tightly fused mass incorporating fibrin (Hatsuoka, M. et al. (1986) Thromb. Res. 42:407-412) thought to be crosslinked to collagen by factor Xlla.
  • the present invention pertains to collagen-based blood coagulating compositions and foams, devices for administering or delivering these compositions and foams to a subject, and methods for coagulating blood in a subject using the compositions, foams, and devices described herein.
  • the collagen-based composition is suitable for packaging in a pressurized aerosol container and for dispensing as a blood coagulating foam and includes fetal and adult collagen and a pharmaceutically acceptable carrier.
  • the fetal and adult collagen can be obtained from animals, e.g., mammals, such as pigs, and marine animals, e.g., marine mammals.
  • a preferred source of collagen is a pig.
  • the fetal collagen is obtained from a near term pig fetus.
  • the composition is in the form of a blood coagulating foam which includes a gas, e.g., an aerosol propellant gas, e.g., a hydrofluorocarbon gas.
  • a gas e.g., an aerosol propellant gas, e.g., a hydrofluorocarbon gas.
  • hydrofluorocarbon gases which can be used in the invention include those in which collagen is soluble.
  • a preferred hydrofluorocarbon gas is 1,1,1,2-tetrafluoroethane (dymel-l,3,4A-P).
  • the fetal and adult collagen can further include a neutralizing solution, e.g., a buffer with a pH greater than 5.0.
  • the fetal collagen can include one type of collagen or can include a mixture of two or more of the types of collagen, e.g., collagen types I, II, III, IV, or V.
  • the adult collagen can include one type of collagen or can include a mixture of two or more of the known types of collagen.
  • the fetal collagen includes collagen type I, collagen type III, and collagen type IV.
  • the adult collagen includes collagen type I and collagen type III.
  • the collagen is at a concentration in the composition of about 1 mg/ml to about 10 mg/ml.
  • the collagen in the composition is at a concentration of about 5 mg/ml.
  • the collagen is fibrillar collagen.
  • Preferred pharmaceutically acceptable carriers include aqueous solutions.
  • the collagen-based composition is suitable for packaging in a pressurized aerosol container and for dispensing as a blood coagulating foam and includes collagen type I, collagen type III, and collagen type IV and a pharmaceutically acceptable carrier.
  • the collagen can also include a neutralizing solution, e.g., a buffer with a pH greater than 5.0, and is preferably obtained from a mammal such as a pig or a marine mammal.
  • a preferred source of collagen is a pig, e.g., fetal pig.
  • the composition is in the form of a blood coagulating foam which includes a gas, e.g., an aerosol propellant gas, e.g., a hydrofluorocarbon gas. Examples of hydrofluorocarbon gases are described herein.
  • the collagen-based composition is suitable for packaging in a pressurized aerosol container and for dispensing as a blood coagulating foam and includes fetal collagen and a pharmaceutically acceptable carrier.
  • the fetal collagen can be obtained from a animal, e.g., a mammal, e.g., pig, or marine animal, e.g., marine mammal. Fetal porcine collagen is preferred.
  • the fetal collagen can further include a neutralizing solution, e.g., a buffer with a pH greater than 5.0.
  • a neutralizing solution e.g., a buffer with a pH greater than 5.0.
  • the composition can be in the form of a blood coagulating foam which includes a gas described herein.
  • the compositions described herein can also be contained within containers, e.g., within containers which include means for dispensing the compositions from the containers in the form of a blood coagulating foam.
  • the invention also pertains to devices for delivering a blood coagulating foam to a subject, e.g., to a site of bleeding on or in a subject.
  • the devices include a container, e.g., a canister, e.g., a glass canister with means for dispensing the compositions from the containers in the form of blood coagulating foams, e.g., a glass canister with appropriate valves and actuators, which has at least one aperture through which contents of the container are dispensed and which holds a composition comprising a collagen- based solution described herein and a compound, e.g., a gas, in which the collagen-based composition is soluble and which exerts a level of pressure sufficient to propel the composition from the container in the form of a blood coagulating foam.
  • a container e.g., a canister, e.g., a glass canister with means for dispensing the compositions from the containers in the form of blood coagulating foams
  • a glass canister with appropriate valves and actuators, which has at least one aperture through which contents of the container are dispensed and which holds a composition comprising a collagen-
  • Preferred compounds which can exert a level of pressure sufficient to propel the composition from the container in the preferred form include gases which are typically used as aerosol propellants, e.g., hydrofluorocarbon gases.
  • gases which are typically used as aerosol propellants e.g., hydrofluorocarbon gases.
  • An example of a hydrofluorocarbon gas which can be used in the invention is 1 , 1 , 1 ,2-tetrafluoroethane.
  • the composition in the device is typically maintained at a pH of about 4.0 to about 6.0, preferably at a pH of about 5.0 to about 6.0, to prevent gelling of the collagen in the container.
  • the devices of the invention can further include an extendible arm having an axial bore therethrough, e.g., extendible hollow arm, e.g., an extendible tube, through which the composition can be delivered to a selected location and which is coaxial with at least one aperture of the container.
  • This arm enables delivery of the composition to areas which are difficult to reach, e.g., body cavities, to coagulate blood, e.g., to reduce or prevent hemorrhaging, e.g., internal hemorrhaging.
  • the devices of the invention can also include a separate compartment in which a neutralizing solution is stored. The neutralizing solution can be released from the same nozzle as the collagen-based solution to accelerate gelling of the collagen-based solution as it exits the device.
  • the invention further pertains to methods for coagulating blood at a site of bleeding in a subject. These methods include administering to the subject the compositions or foams described herein.
  • the compositions or foams can be dispensed from the devices of the invention.
  • Fig. 1 is a schematic representation of a first container embodying one form of the invention.
  • Fig. 2 is a schematic representation of a second container embodying another form of the invention.
  • compositions and foams which are capable of coagulating blood in a subject. These compositions can be inserted into the devices of the invention for administration to a subject.
  • the composition of the invention is a composition which is suitable for packaging in a pressurized aerosol container and for dispensing as a blood coagulating foam and which comprises fetal and adult collagen and a pharmaceutically acceptable carrier.
  • coagulate as used herein has its art recognized meaning and refers to a solidification or change from a fluid state to a semisolid mass. When referring to blood, the term “coagulate” means the formation of blood clot.
  • compositions and foams of the invention results in a decrease in bleeding at the site of application or administration of the composition as compared to the bleeding at the site in the absence of application or administration of the composition.
  • fetal collagen refers to collagen obtained from an animal, e.g., a mammal, during gestation of the animal.
  • the fetal collagen is obtained from a mammal.
  • mammals from which the fetal collagen can be obtained include pigs and marine animals, e.g., marine mammals.
  • the collagen can be isolated according to the methods set forth in WO 96/15818, published on May 30, 1996, the contents of which are incorporated herein by reference.
  • the fetal collagen is obtained from a pig.
  • Preferred gestational ages of a pig for harvesting collagen include gestational days near term, e.g., near birth, e.g., about day 100 to about day 1 14 or 115.
  • the fetal collagen includes a mixture of collagen type I, collagen type III, and collagen type IV.
  • the phrase "adult collagen" as used herein refers to collagen obtained from an animal, e.g., a mammal, after birth.
  • the adult collagen includes a mixture of collagen type I and collagen type III.
  • the collagen is at a concentration in the composition of about 1 mg/ml to about 10 mg/ml. In a preferred embodiment, the collagen in the composition is at a concentration of about 5 mg/ml.
  • the collagen used in the compositions and foams of the invention can be in the form of collagen microfibrils.
  • collagen microfibril refers to collagen in the form described in Williams, B.R. et al. (1978) J. Biol. Chem. 253 (18):6578-6585, the contents of which are incoporated herein by reference.
  • the collagen microfibrils are prepared as a semisolid (viscous) pellet of collagen microfibrils resulting from centrifugation of a neutralized solution of collagen.
  • the collagen can be neutralized by liquid 0.01-1.0 N NaOH, 0.1- 10% ammonium hydroxide, or other known neutralizing solutions, before spinning in a centrifuge to yield a microfibrillar collagen pellet mass.
  • the liquid content of the microfibrillar collagen pellet mass can be manipulated by the relative centrifugal force employed. For example, the stronger the centrifugal force, the less liquid and the higher the resulting concentration of microfibrillar collagen (e.g., from about 10 to about 100 mg/ml).
  • the resultant semisolid pellet of neutralized microfibrillar collagen can be manipulated like a fluid such that it can be propelled from, for example, a device of the present invention, onto or into a site of bleeding.
  • microfibrillar collagen Since the microfibrillar collagen is already neutral, no gelling is required. However, the density of this form of collagen allows it to remain in place at the desired site of bleeding.
  • the structure of the microfibrillar collagen provides the surface to initiate the clotting cascade at the site of bleeding.
  • Methods for purifying collagen in the microfibrillar form typically include the steps of extracting proteins from, for example, the skin of an animal, e.g., chicken, mammal, e.g., a marine mammal, a cow, goat, sheep, or, preferably, a pig, e.g., a fetal or newborn pig.
  • This extraction step involves the use of organic acid such as formic or acetic acid.
  • the collagen is then precipitated from the extract by salt (e.g., sodium chloride up to 3.0M or ammonium sulfate up to 50%) and collected by centrifugation.
  • the collagen is then redissolved in organic acid and concentrated.
  • the collagen can then be used or subjected to as many rounds, e.g., two rounds, of salt precipitation and centrifugation as desired before concentrating and using in the present invention.
  • a preferred collagen concentration used to make microfibrillar collagen is 4.0 to 10.0 mg/ml.
  • An alternative method for purifying collagen in the microfibrillar form includes a method in which pepsin is included in the extraction acid solution, with all other steps the same as described above, with the additional updated steps described below.
  • Neutralizing solutions used in the present invention include solutions which can raise the pH of the collagen-based compositions and foams of the invention such that the collagen in these compositions and foams gels at an accelerated pace compared to the collagen in compositions and foams in the absence of the neutralizing solutions.
  • the devices described herein can also include a compartment, preferably a compartment which is separate from the collagen-containing compartment, which includes the neutralizing solution.
  • This neutralizing solution can then be released from the device through an independent aperture in the same nozzle as the collagen.
  • the separate compartment and aperture ensure that the collagen remains at an acidic pH, e.g., pH 5.0, and retains fluidity in the device.
  • the coincident spraying allows for mixing of the collagen and neutralizing solution before and upon contact with the site of bleeding, where gelling and clotting of the collagen, due to the presence of the neutralizing solution, is more rapid than gelling and clotting of the collagen in the absence of the neutralizing solution.
  • neutralizing solutions which can be used in the present invention include solutions with a pH which is greater than 5.0.
  • neutralizing solutions used in the present invention have a pH of between about 8.0 and 11.0 or greater.
  • neutralizing solutions include buffers such as Good's buffers at the relevant pHs.
  • Good's buffers at pH's between about 5.0 and 8.0 include MES, ADA, PIPES, ACES, BES, MOPS, TES, and HEPES.
  • Good's buffers at pHs between 8.0 and 11.0 include EPPS, Tricine, Bicine, CHES and CAPS. See, e.g., page 125 of D. Freifelder "Physical Biochemistry Applications to Biochemistry and Molecular Biology", 2nd ed. (W.H. Freeman and Company, New York, NY, 1982).
  • Good's buffers as well as additional Good's buffers which can be used in the present invention are commercially available from Sigma Chemical Company, St. Louis, Missouri.
  • Examples of other neutralizing solutions which can be used in the present invention include phosphate buffers such as dibasic sodium phosphate ⁇ see, e.g., page 123 of D. Freifelder "Physical Biochemistry Applications to Biochemistry and Molecular Biology", 2nd ed. (W.H.
  • buffers such as boric acid, CAPSO and CHES at concentrations ranging from about 0.01 to about 0.5 M at, for example, a pH of 9.5, sodium bicarbonate (e.g., 0.1 to l.OM), and glycine (0.01 to 0.5M at, for example, a pH of 9.5).
  • pharmaceutically acceptable carrier is intended to include any and all solutions, solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like, compatible with pharmaceutical administration.
  • Preferred pharmaceutically acceptable carriers include sterile saline and aqueous buffer solutions.
  • the pharmaceutically acceptable carriers include sterile aqueous solutions with very low conductivity, e.g., sterile aqueous solutions free of dissolved electrolytes such as salts and acids, e.g., Milli-QTM water. The use of such carriers is well known in the art.
  • the composition which is suitable for packaging in a pressurized aerosol container and for dispensing as a blood coagulating foam includes collagen type I, collagen type III, and collagen type IV and a pharmaceutically acceptable carrier.
  • the collagen is obtained from an animal, e.g., a mammal. Examples of mammals from which the collagen can be obtained includes fetal or adult pigs, and marine mammals.
  • the collagen is fetal collagen obtained from a pig.
  • the different types of collagen can be mixed together in various ratios to obtain a composition which is capable of coagulating blood, e.g., decreasing clotting time, upon contact with a site at which unwanted bleeding is occurring.
  • the composition can be in the form of a foam as described herein.
  • the collagen is at a concentration in the composition of about 1 mg/ml to about 10 mg/ml. In a preferred embodiment, the collagen in the composition is at a concentration of about 5 mg/ml.
  • the composition which is suitable for packaging in a pressurized aerosol container and for dispensing as a blood coagulating foam includes fetal collagen and a pharmaceutically acceptable carrier.
  • the fetal collagen can be obtained from a mammal, e.g., any of the mammals described herein.
  • the fetal collagen is obtained from a fetal pig at the selected gestational ages described herein.
  • the fetal collagen can include one type of collagen or a mixture of two or more types of collagen described herein.
  • the collagen is at a concentration in the composition of about 1 mg/ml to about 10 mg/ml. In a preferred embodiment, the collagen in the composition is at a concentration of about 5 mg/ml.
  • compositions can be in the form of a blood coagulating foam as described herein.
  • compositions can also be contained within containers, e.g., containers with means for dispensing the composition from the container as a blood coagulating foam. Such means are described in more detail herein.
  • the invention pertains to a device for delivering a blood coagulating composition or foam.
  • the device typically includes a container which holds a blood coagulating composition described herein.
  • the composition, the first component is in the container together with a second component.
  • the second component is a compound in which the composition is soluble and which exerts a level of pressure sufficient to propel the composition from the container (i.e., the composition can be dispensed from the container) in the form of a blood coagulating foam.
  • the compound in which the collagen is soluble and which exerts a level of pressure sufficient to propel the composition from the container in the form of a foam is a gas, e.g., a gas which can be used as a aerosol propeliant.
  • hydrofluorocarbon gases examples include 1,1,1,2-tetrafluoroethane, hydrofluorocarbon (HFC)-l 52A, and HFC-2273A.
  • gases which can be used according to the invention include dimethyl ether, isobutane, propane, n-butane, nitrous oxide, suva, and mixtures thereof.
  • A-46 an industry designation for a mixture of n-butane, isobutane, and propane in proportions chosen such that the blend has a vapor pressure of 46 psig at 70°F
  • the gases are typically at a concentration within the device of at least about 5 to about 30%, preferably at least about 10 to about 20%, more preferably at least about 15% by weight, e.g., by weight of the entire composition, and a pressure, e.g., vapor pressure, from about 30 to about 70 psig at room temperature, e.g., 70°F.
  • the collagen compositions are preferably in the form of a solution, e.g., a liquid containing dissolved substance, e.g., an aqueous carrier containing dissolved collagen.
  • a solution e.g., a liquid containing dissolved substance, e.g., an aqueous carrier containing dissolved collagen.
  • the collagen compositions form a blood coagulating foam.
  • the term "foam” refers to a mass of gas bubbles, e.g., hydrofluorocarbon gas bubbles, in a liquid-film matrix, e.g., a liquid- protein film matrix, e.g., an aqueous-collagen film matrix.
  • the foam can then be easily delivered to the selected site through an aperture, e.g., a small diameter aperture, in the device.
  • the following parameters can be manipulated: (1) pH of the composition; (2) concentration of collagen in the composition; (3) the type of pharmaceutically acceptable carrier in which the collagen is in solution; and (4) the amount and temperature of the gas within the device.
  • the pH of the composition be as close to neutrality, i.e., pH 7.0, as possible.
  • the pH of the composition within the device approaches neutrality, the composition will tend to form a gel. Formation of a gel within the device is typically undesirable as the gels are difficult to release or dispense from the device.
  • the pH of the composition within the device is generally maintained at a pH as close to neutrality as possible but which will not initiate the formation of a gel.
  • a preferred pH range is from about 4.0 to about 6.0, preferably from about 5.0 to 6.0.
  • concentration of collagen in the composition is increased, the composition will begin to form a gel at a lower, i.e., more acidic, pH.
  • the concentration of the collagen in the composition is greater than 5 mg/ml, the composition will begin to form a gel at a pH of about 5.0.
  • the type of pharmaceutically acceptable carrier which can be used according to the invention depends upon, for example, the ability of the carrier to maintain the collagen in solution and the compatibility of the carrier with pharmaceutical administration in a subject, e.g., a human.
  • a subject e.g., a human.
  • Various carriers having these preferred characteristics can be used in the invention and are described herein.
  • the amount and temperature of the gas within the device can be regulated to maintain the compositions in the form of a solution.
  • the device 10 includes a container 12 with the appropriate valves 14 and actuators 16 to facilitate release of the composition 18 of the invention through nozzle 19.
  • the container 12 can be any container which can hold the composition 18 without detrimentally affecting the form or activity of the composition.
  • preferred containers 12 include containers, e.g., bottles or canisters, which are composed of glass.
  • the container 12 is composed of glass and coated with plastic to prevent shattering upon release of the collagen composition.
  • the device can also be fitted with desired extensions, e.g., delivery tubes, through which the composition can be delivered to locations which are difficult to reach, e.g., body cavities (to reduce internal bleeding).
  • desired extensions e.g., delivery tubes
  • the device 10 is fitted with an extendible arm, e.g., tube 20, with a lumen 22 through which the composition can be delivered to a selected location.
  • the elements of aerosol delivery devices such as those described in Figs. 1 and 2 for delivering proteins to desired locations are known in the art.
  • aerosol delivery devices for delivering proteins to desired locations see U.S. Patent Nos. 5, 399,347, 5,356,614 and 5,196,185.
  • the invention pertains to methods for coagulating blood at a site of bleeding in or on a subject. These methods include administering to the subject, e.g., at a site of bleeding, a composition or foam of the invention.
  • administering refers to the delivery of the compositions or foams described herein to a subject by a method or route which allows the composition to perform its intended function of coagulating blood. Examples of routes of administration which can be used in this method include percutaneous, e.g., topical, administration, parenteral, e.g., subcutaneous, administration, and intraperitoneal administration.
  • a preferred method of administering a composition or foam of the present invention is percutaneous, e.g., topical, administration.
  • the composition or foam is administered to the subject by spraying the composition or foam directly onto (or into, e.g., into the peritoneal cavity, in the case of internal bleeding) a wound site or a site where hemorrhaging is occurring.
  • spraying the composition or foam directly onto or into, e.g., into the peritoneal cavity, in the case of internal bleeding
  • This can be accomplished by inserting the composition into a device described herein and dispensing the composition in the form of a blood coagulating foam from the device.
  • Subjects who can be treated according to the methods of the invention include mammals, particularly humans, susceptible to a disorder or injury which can result in unwanted bleeding.
  • subjects who can be treated according to the method of the invention include mammals, e.g., humans, suffering from injuries, e.g., traumatic injuries, resulting in internal or external hemorrhaging.
  • injuries e.g., traumatic injuries, resulting in internal or external hemorrhaging.
  • Non-limiting examples of such persons include military personnel with combat injuries, persons with injuries received as a result of accidents, and persons suffering from hemorrhaging associated with surgical procedures.
  • Laparotomies were performed on six mice to expose the liver in each mouse. A one-half square centimeter of liver tissue was removed to initiate bleeding and the resultant bleeding was timed.
  • a glass aerosol can which contained 5 mg/ml of acid extracted fetal porcine collagen including collagen types I, III, and IV and 15% by weight of 1,1,1,2-tetrafluoroethane (dymel-l,3,4A-P) at a pressure of 70 psig, the collagen solution was sprayed onto the bleeding sites of the mouse livers. A clot formed within about 2.5 minutes upon administration of the collagen and loss of blood was curtailed. The clot was formed on the livers of the test mice in a time period which was significantly shorter than the clot formation on the livers of control mice.

Abstract

Compositions destinées à la coagulation du sang, à base de collagène, dispositifs permettant d'administrer lesdites compositions à un sujet et procédés permettant de faire coaguler le sang chez un sujet à l'aide des compositions et dispositifs décrits. Les compositions préférées qui peuvent être utilisées selon la présente invention sont des compositions qui contiennent du collagène foetal et adulte et un excipient acceptable sur le plan pharmaceutique, des compositions qui contiennent du collagène de type I, du collagène de type II et du collagène de type III et un excipient acceptable sur le plan pharmaceutique et des compositions qui contiennent du collagène foetal et un excipient acceptable sur le plan pharmaceutique. Lesdites compositions peuvent être administrées sur un site de saignement non désiré, par ex. sur une blessure, sous forme de mousse de coagulation du sang appliquée à l'aide des dispositifs selon la présente invention.
PCT/US1997/014263 1996-08-13 1997-08-13 Mousses destinees a la coagulation du sang, a base de collagene, procede et dispositifs permettant de les administrer WO1998006444A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU40652/97A AU4065297A (en) 1996-08-13 1997-08-13 Collagen-based blood coagulating foams, method and devices for their delivery

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US69681096A 1996-08-13 1996-08-13
US08/696,810 1996-08-13

Publications (1)

Publication Number Publication Date
WO1998006444A1 true WO1998006444A1 (fr) 1998-02-19

Family

ID=24798643

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1997/014263 WO1998006444A1 (fr) 1996-08-13 1997-08-13 Mousses destinees a la coagulation du sang, a base de collagene, procede et dispositifs permettant de les administrer

Country Status (2)

Country Link
AU (1) AU4065297A (fr)
WO (1) WO1998006444A1 (fr)

Cited By (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001066835A1 (fr) * 2000-03-06 2001-09-13 Tei Biosciences, Inc. Procede et dispositif de coagulation de biopolymere dans un flux uniforme
WO2001097873A2 (fr) * 2000-06-20 2001-12-27 Wolfgang Biering Collagene liquide hemostatique
US8834451B2 (en) 2002-10-28 2014-09-16 Smith & Nephew Plc In-situ wound cleansing apparatus
US8998866B2 (en) 2010-07-02 2015-04-07 Smith & Nephew Plc Provision of wound filler
US9044569B2 (en) 2004-04-28 2015-06-02 Smith & Nephew Plc Wound dressing apparatus and method of use
US9198801B2 (en) 2004-04-05 2015-12-01 Bluesky Medical Group, Inc. Flexible reduced pressure treatment appliance
US9956121B2 (en) 2007-11-21 2018-05-01 Smith & Nephew Plc Wound dressing
US10058642B2 (en) 2004-04-05 2018-08-28 Bluesky Medical Group Incorporated Reduced pressure treatment system
US10071190B2 (en) 2008-02-27 2018-09-11 Smith & Nephew Plc Fluid collection
US10143784B2 (en) 2007-11-21 2018-12-04 T.J. Smith & Nephew Limited Suction device and dressing
US10159604B2 (en) 2010-04-27 2018-12-25 Smith & Nephew Plc Wound dressing and method of use
US10207035B2 (en) 2004-05-21 2019-02-19 Smith & Nephew, Inc. Flexible reduced pressure treatment appliance
US10265445B2 (en) 2002-09-03 2019-04-23 Smith & Nephew, Inc. Reduced pressure treatment system
US10537657B2 (en) 2010-11-25 2020-01-21 Smith & Nephew Plc Composition I-II and products and uses thereof
US10675392B2 (en) 2007-12-06 2020-06-09 Smith & Nephew Plc Wound management
US11045598B2 (en) 2007-11-21 2021-06-29 Smith & Nephew Plc Vacuum assisted wound dressing
US11253399B2 (en) 2007-12-06 2022-02-22 Smith & Nephew Plc Wound filling apparatuses and methods
US11638666B2 (en) 2011-11-25 2023-05-02 Smith & Nephew Plc Composition, apparatus, kit and method and uses thereof
US11931226B2 (en) 2013-03-15 2024-03-19 Smith & Nephew Plc Wound dressing sealant and use thereof
US11938231B2 (en) 2010-11-25 2024-03-26 Smith & Nephew Plc Compositions I-I and products and uses thereof

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4427651A (en) * 1981-06-25 1984-01-24 Serapharm Michael Stroetmann Enriched plasma derivative for enhancement of wound closure and coverage
US5196185A (en) * 1989-09-11 1993-03-23 Micro-Collagen Pharmaceutics, Ltd. Collagen-based wound dressing and method for applying same
JPH06166616A (ja) * 1992-12-01 1994-06-14 Nichirei Corp 化粧料
US5376359A (en) * 1992-07-07 1994-12-27 Glaxo, Inc. Method of stabilizing aerosol formulations
WO1996015818A1 (fr) * 1994-11-22 1996-05-30 Tissue Engineering, Inc. Mousses biopolymeres contenant des matieres particulaires en matrice extracellulaire

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4427651A (en) * 1981-06-25 1984-01-24 Serapharm Michael Stroetmann Enriched plasma derivative for enhancement of wound closure and coverage
US5196185A (en) * 1989-09-11 1993-03-23 Micro-Collagen Pharmaceutics, Ltd. Collagen-based wound dressing and method for applying same
US5356614A (en) * 1989-09-11 1994-10-18 Mixro-Collagen Pharmaceutics, Ltd. Process of preparing microparticulate collagen collagen-based products produced thereby and method of applying same
US5376359A (en) * 1992-07-07 1994-12-27 Glaxo, Inc. Method of stabilizing aerosol formulations
JPH06166616A (ja) * 1992-12-01 1994-06-14 Nichirei Corp 化粧料
WO1996015818A1 (fr) * 1994-11-22 1996-05-30 Tissue Engineering, Inc. Mousses biopolymeres contenant des matieres particulaires en matrice extracellulaire

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
PATENT ABSTRACTS OF JAPAN vol. 018, no. 495 (C - 1250) 16 September 1994 (1994-09-16) *

Cited By (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001066835A1 (fr) * 2000-03-06 2001-09-13 Tei Biosciences, Inc. Procede et dispositif de coagulation de biopolymere dans un flux uniforme
WO2001097873A2 (fr) * 2000-06-20 2001-12-27 Wolfgang Biering Collagene liquide hemostatique
WO2001097873A3 (fr) * 2000-06-20 2002-03-07 Wolfgang Biering Collagene liquide hemostatique
AT412445B (de) * 2000-06-20 2005-03-25 Biering Wolfgang Flüssiges collagen-hämostatikum
US11298454B2 (en) 2002-09-03 2022-04-12 Smith & Nephew, Inc. Reduced pressure treatment system
US10265445B2 (en) 2002-09-03 2019-04-23 Smith & Nephew, Inc. Reduced pressure treatment system
US11376356B2 (en) 2002-09-03 2022-07-05 Smith & Nephew, Inc. Reduced pressure treatment system
US10842678B2 (en) 2002-10-28 2020-11-24 Smith & Nephew Plc Apparatus for aspirating, irrigating and cleansing wounds
US9205001B2 (en) 2002-10-28 2015-12-08 Smith & Nephew Plc Apparatus for aspirating, irrigating and cleansing wounds
US9387126B2 (en) 2002-10-28 2016-07-12 Smith & Nephew Plc Apparatus for aspirating, irrigating and cleansing wounds
US10278869B2 (en) 2002-10-28 2019-05-07 Smith & Nephew Plc Apparatus for aspirating, irrigating and cleansing wounds
US9844473B2 (en) 2002-10-28 2017-12-19 Smith & Nephew Plc Apparatus for aspirating, irrigating and cleansing wounds
US9844474B2 (en) 2002-10-28 2017-12-19 Smith & Nephew Plc Apparatus for aspirating, irrigating and cleansing wounds
US8834451B2 (en) 2002-10-28 2014-09-16 Smith & Nephew Plc In-situ wound cleansing apparatus
US10842919B2 (en) 2004-04-05 2020-11-24 Smith & Nephew, Inc. Reduced pressure treatment system
US11730874B2 (en) 2004-04-05 2023-08-22 Smith & Nephew, Inc. Reduced pressure treatment appliance
US10363346B2 (en) 2004-04-05 2019-07-30 Smith & Nephew, Inc. Flexible reduced pressure treatment appliance
US10058642B2 (en) 2004-04-05 2018-08-28 Bluesky Medical Group Incorporated Reduced pressure treatment system
US10350339B2 (en) 2004-04-05 2019-07-16 Smith & Nephew, Inc. Flexible reduced pressure treatment appliance
US10105471B2 (en) 2004-04-05 2018-10-23 Smith & Nephew, Inc. Reduced pressure treatment system
US9198801B2 (en) 2004-04-05 2015-12-01 Bluesky Medical Group, Inc. Flexible reduced pressure treatment appliance
US9950100B2 (en) 2004-04-28 2018-04-24 Smith & Nephew Plc Negative pressure wound therapy dressing system
US10039868B2 (en) 2004-04-28 2018-08-07 Smith & Nephew Plc Dressing and apparatus for cleansing the wounds
US10758424B2 (en) 2004-04-28 2020-09-01 Smith & Nephew Plc Dressing and apparatus for cleansing the wounds
US10758425B2 (en) 2004-04-28 2020-09-01 Smith & Nephew Plc Negative pressure wound therapy dressing system
US9044569B2 (en) 2004-04-28 2015-06-02 Smith & Nephew Plc Wound dressing apparatus and method of use
US10207035B2 (en) 2004-05-21 2019-02-19 Smith & Nephew, Inc. Flexible reduced pressure treatment appliance
US11701266B2 (en) 2007-11-21 2023-07-18 Smith & Nephew Plc Vacuum assisted wound dressing
US10016309B2 (en) 2007-11-21 2018-07-10 Smith & Nephew Plc Wound dressing
US10555839B2 (en) 2007-11-21 2020-02-11 Smith & Nephew Plc Wound dressing
US10143784B2 (en) 2007-11-21 2018-12-04 T.J. Smith & Nephew Limited Suction device and dressing
US10744041B2 (en) 2007-11-21 2020-08-18 Smith & Nephew Plc Wound dressing
US11766512B2 (en) 2007-11-21 2023-09-26 T.J.Smith And Nephew, Limited Suction device and dressing
US10231875B2 (en) 2007-11-21 2019-03-19 Smith & Nephew Plc Wound dressing
US11179276B2 (en) 2007-11-21 2021-11-23 Smith & Nephew Plc Wound dressing
US9956121B2 (en) 2007-11-21 2018-05-01 Smith & Nephew Plc Wound dressing
US11045598B2 (en) 2007-11-21 2021-06-29 Smith & Nephew Plc Vacuum assisted wound dressing
US11364151B2 (en) 2007-11-21 2022-06-21 Smith & Nephew Plc Wound dressing
US11351064B2 (en) 2007-11-21 2022-06-07 Smith & Nephew Plc Wound dressing
US11129751B2 (en) 2007-11-21 2021-09-28 Smith & Nephew Plc Wound dressing
US11344663B2 (en) 2007-11-21 2022-05-31 T.J.Smith And Nephew, Limited Suction device and dressing
US10675392B2 (en) 2007-12-06 2020-06-09 Smith & Nephew Plc Wound management
US11253399B2 (en) 2007-12-06 2022-02-22 Smith & Nephew Plc Wound filling apparatuses and methods
US10071190B2 (en) 2008-02-27 2018-09-11 Smith & Nephew Plc Fluid collection
US11141520B2 (en) 2008-02-27 2021-10-12 Smith & Nephew Plc Fluid collection
US10159604B2 (en) 2010-04-27 2018-12-25 Smith & Nephew Plc Wound dressing and method of use
US11090195B2 (en) 2010-04-27 2021-08-17 Smith & Nephew Plc Wound dressing and method of use
US11058587B2 (en) 2010-04-27 2021-07-13 Smith & Nephew Plc Wound dressing and method of use
US8998866B2 (en) 2010-07-02 2015-04-07 Smith & Nephew Plc Provision of wound filler
US9801761B2 (en) 2010-07-02 2017-10-31 Smith & Nephew Plc Provision of wound filler
US11730876B2 (en) 2010-11-25 2023-08-22 Smith & Nephew Plc Composition I-II and products and uses thereof
US10537657B2 (en) 2010-11-25 2020-01-21 Smith & Nephew Plc Composition I-II and products and uses thereof
US11938231B2 (en) 2010-11-25 2024-03-26 Smith & Nephew Plc Compositions I-I and products and uses thereof
US11638666B2 (en) 2011-11-25 2023-05-02 Smith & Nephew Plc Composition, apparatus, kit and method and uses thereof
US11931226B2 (en) 2013-03-15 2024-03-19 Smith & Nephew Plc Wound dressing sealant and use thereof

Also Published As

Publication number Publication date
AU4065297A (en) 1998-03-06

Similar Documents

Publication Publication Date Title
WO1998006444A1 (fr) Mousses destinees a la coagulation du sang, a base de collagene, procede et dispositifs permettant de les administrer
AU2012318257B2 (en) Hemostatic compositions
US5330974A (en) Therapeutic fibrinogen compositions
AU666899B2 (en) Reconstituted platelet membrane vesicles
EP0172710B1 (fr) Agent hémostatique
AU2011260260B2 (en) Process for making dry and stable hemostatic compositions
WO1996040033A1 (fr) Timbre hemostatique non biologique
US20070087061A1 (en) Method and composition for creating and/or activating a platelet-rich gel by contact with a porous particulate material, for use in wound care, tissue adhesion, or as a matrix for delivery of therapeutic components
JP5868592B2 (ja) ケラチンバイオマテリアルを含有する創傷治癒組成物
US20030211137A1 (en) Foam-forming wound dressing
WO2001097871A2 (fr) Granules hémostatiques de collagène
JPH07503719A (ja) ヒルジンおよび合成トロンビン抑制因子のための解毒薬
WO2014114719A1 (fr) Compositions hémostatiques
WO2021176457A1 (fr) Compositions anti-hémorragies
AU2013366544B2 (en) Sealant compositions
EP0686401A2 (fr) Colle pour tissu vivant et coagulant sanguin
JP2024514093A (ja) 血液凝固活性を有するペプチドとこの用途

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU CA JP

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: JP

Ref document number: 1998509999

Format of ref document f/p: F

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA